Blueshift Asset Management LLC Purchases 537 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Blueshift Asset Management LLC grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 14.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,343 shares of the company’s stock after buying an additional 537 shares during the quarter. Blueshift Asset Management LLC’s holdings in TransMedics Group were worth $682,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vaughan Nelson Investment Management L.P. bought a new position in TransMedics Group during the second quarter valued at about $39,862,000. Driehaus Capital Management LLC grew its position in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the period. Principal Financial Group Inc. grew its position in shares of TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the period. Hood River Capital Management LLC purchased a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $18,854,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $16,086,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $87.11 on Thursday. TransMedics Group, Inc. has a twelve month low of $67.77 and a twelve month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.92 billion, a P/E ratio of 92.67 and a beta of 2.08. The business’s 50-day moving average price is $114.84 and its two-hundred day moving average price is $136.79.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TMDX has been the subject of several research reports. Needham & Company LLC reissued a “hold” rating and set a $109.00 price objective on shares of TransMedics Group in a report on Friday, November 22nd. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. JPMorgan Chase & Co. lowered their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Robert W. Baird cut their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Finally, Oppenheimer lowered their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The trade was a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,958 shares of company stock valued at $3,470,328. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.